IPA (ImmunoPrecise Antibodies) ROCE % : -24.53% (As of Oct. 2024)

View and export this data going back to 2011. Start your Free Trial

What is ImmunoPrecise Antibodies ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. ImmunoPrecise Antibodies's annualized ROCE % for the quarter that ended in Oct. 2024 was -24.53%.

ImmunoPrecise Antibodies ROCE % Historical Data

The historical data trend for ImmunoPrecise Antibodies's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ImmunoPrecise Antibodies ROCE % Chart

ImmunoPrecise Antibodies Annual Data

Trend

Dec14

Dec15

Apr17

Apr18

Apr19

Apr20

Apr21

Apr22

Apr23

Apr24

ROCE %

Get a 7-Day Free Trial

-18.51

-13.15

-21.61

-34.23

-45.98

ImmunoPrecise Antibodies Quarterly Data
	Jan20	Apr20	Jul20	Oct20	Jan21	Apr21	Jul21	Oct21	Jan22	Apr22	Jul22	Oct22	Jan23	Apr23	Jul23	Oct23	Jan24	Apr24	Jul24	Oct24
ROCE %	Get a 7-Day Free Trial															-14.68	-20.27	-122.63	-38.13	-24.53

ImmunoPrecise Antibodies ROCE % Calculation

ImmunoPrecise Antibodies's annualized ROCE % for the fiscal year that ended in Apr. 2024 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Apr. 2024 )		(A: Apr. 2023 )		(A: Apr. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Apr. 2024 )		(A: Apr. 2023 )		(A: Apr. 2024 )
	=	-20.977	/	( ( (57.708 - 4.39)	+	(43.87 - 5.941) )	/ 2 )
	=	-20.977	/	( (53.318	+	37.929)	/ 2 )
	=	-20.977	/	45.6235
	=	-45.98 %

ImmunoPrecise Antibodies's ROCE % of for the quarter that ended in Oct. 2024 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Oct. 2024 )		(Q: Jul. 2024 )		(Q: Oct. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Oct. 2024 )		(Q: Jul. 2024 )		(Q: Oct. 2024 )
	=	-8.544	/	( ( (43.24 - 8.147)	+	(43.587 - 9.02) )	/ 2 )
	=	-8.544	/	( ( 35.093	+	34.567 )	/ 2 )
	=	-8.544	/	34.83
	=	-24.53 %

(1) Note: The EBIT data used here is four times the quarterly (Oct. 2024) EBIT data.

ImmunoPrecise Antibodies (NAS:IPA) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

ImmunoPrecise Antibodies ROCE % Related Terms

Thank you for viewing the detailed overview of ImmunoPrecise Antibodies's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

ImmunoPrecise Antibodies Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ImmunoPrecise Antibodies Ltd (NAS:IPA) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

TQB:Germany

Address

3204 - 4464 Markham Street, Victoria, BC, CAN, V8Z 7X8

Website

https://www.ipatherapeutics.com

ImmunoPrecise Antibodies Ltd is a biotechnology company that leverages multi-omics modeling and complex artificial intelligence through a series proprietary and patented technologies. The company owns an integrated end-to-end suite of capabilities to support the development of therapeutic antibodies and are known for solving very complex industry challenges.